Annual Operating Expenses
$771.42 M
+$126.15 M+19.55%
December 31, 2022
Summary
- As of February 11, 2025, MRTX annual total operating expenses is $771.42 million, with the most recent change of +$126.15 million (+19.55%) on December 31, 2022.
- During the last 3 years, MRTX annual operating expenses has risen by +$545.99 million (+242.19%).
Performance
MRTX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Operating Expenses
$186.77 M
-$12.91 M-6.47%
September 30, 2023
Summary
- As of February 11, 2025, MRTX quarterly total operating expenses is $186.77 million, with the most recent change of -$12.91 million (-6.47%) on September 30, 2023.
- Over the past year, MRTX quarterly operating expenses has dropped by -$5.11 million (-2.66%).
Performance
MRTX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
MRTX Operating Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +19.6% | -2.7% |
3 y3 years | +242.2% | +86.6% |
5 y5 years | +978.4% | +545.4% |
MRTX Operating Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | -16.4% | -11.9% | -2.2% |
5 y | 5-year | at high | -70.8% | -11.9% | -59.7% |
alltime | all time | at high | -98.5% | -11.9% | -99.8% |
Mirati Therapeutics Operating Expenses History
Date | Annual | Quarterly |
---|---|---|
Sep 2023 | - | $186.77 M(-6.5%) |
Jun 2023 | - | $199.68 M(-0.2%) |
Mar 2023 | - | $200.17 M(-5.6%) |
Dec 2022 | $771.42 M(+19.6%) | $212.06 M(+10.5%) |
Sep 2022 | - | $191.87 M(+5.1%) |
Jun 2022 | - | $182.57 M(-1.3%) |
Mar 2022 | - | $184.93 M(-6.3%) |
Dec 2021 | $645.27 M(+68.6%) | $197.37 M(+30.5%) |
Sep 2021 | - | $151.29 M(-7.9%) |
Jun 2021 | - | $164.19 M(+24.0%) |
Mar 2021 | - | $132.42 M(+22.6%) |
Dec 2020 | $382.76 M(+69.8%) | $108.04 M(+7.9%) |
Sep 2020 | - | $100.10 M(+18.0%) |
Jun 2020 | - | $84.86 M(-5.5%) |
Mar 2020 | - | $89.75 M(+19.4%) |
Dec 2019 | $225.44 M(+95.1%) | $75.17 M(+29.5%) |
Sep 2019 | - | $58.05 M(+20.4%) |
Jun 2019 | - | $48.22 M(+9.6%) |
Mar 2019 | - | $44.00 M(+32.8%) |
Dec 2018 | $115.55 M(+61.5%) | $33.13 M(+14.5%) |
Sep 2018 | - | $28.94 M(+0.9%) |
Jun 2018 | - | $28.67 M(+15.5%) |
Mar 2018 | - | $24.81 M(+36.1%) |
Dec 2017 | $71.53 M(-14.6%) | $18.23 M(+9.8%) |
Sep 2017 | - | $16.60 M(-10.8%) |
Jun 2017 | - | $18.62 M(+2.9%) |
Mar 2017 | - | $18.09 M(-8.9%) |
Dec 2016 | $83.78 M(+29.5%) | $19.85 M(+1.4%) |
Sep 2016 | - | $19.58 M(-11.9%) |
Jun 2016 | - | $22.23 M(+0.5%) |
Mar 2016 | - | $22.12 M(+19.6%) |
Dec 2015 | $64.71 M(+66.9%) | $18.49 M(-1.3%) |
Sep 2015 | - | $18.72 M(+20.7%) |
Jun 2015 | - | $15.52 M(+29.5%) |
Mar 2015 | - | $11.99 M(+14.8%) |
Dec 2014 | $38.77 M | $10.44 M(-1.0%) |
Sep 2014 | - | $10.55 M(+4.1%) |
Jun 2014 | - | $10.13 M(+32.6%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2014 | - | $7.64 M(+11.4%) |
Dec 2013 | $30.97 M(+51.1%) | $6.86 M(-25.5%) |
Sep 2013 | - | $9.21 M(+33.6%) |
Jun 2013 | - | $6.89 M(-13.8%) |
Mar 2013 | - | $8.00 M(+25.5%) |
Dec 2012 | $20.50 M(+59.5%) | $6.37 M(+6.8%) |
Sep 2012 | - | $5.97 M(+26.0%) |
Jun 2012 | - | $4.73 M(+38.3%) |
Mar 2012 | - | $3.42 M(-18.5%) |
Dec 2011 | $12.85 M(-24.7%) | $4.20 M(+33.4%) |
Sep 2011 | - | $3.15 M(+6.8%) |
Jun 2011 | - | $2.95 M(+0.6%) |
Mar 2011 | - | $2.93 M(-10.4%) |
Dec 2010 | $17.06 M(-32.9%) | $3.27 M(-36.7%) |
Sep 2010 | - | $5.17 M(+37.1%) |
Jun 2010 | - | $3.77 M(-21.8%) |
Mar 2010 | - | $4.82 M(-16.9%) |
Dec 2009 | $25.45 M(-22.9%) | $5.81 M(+6.0%) |
Sep 2009 | - | $5.48 M(-1.7%) |
Jun 2009 | - | $5.58 M(-9.8%) |
Mar 2009 | - | $6.18 M(+124.0%) |
Dec 2008 | $33.02 M(-19.4%) | $2.76 M(-70.5%) |
Sep 2008 | - | $9.34 M(-20.3%) |
Jun 2008 | - | $11.73 M(+18.2%) |
Mar 2008 | - | $9.92 M(-27.6%) |
Dec 2007 | $40.96 M(+141.2%) | $13.70 M(+39.8%) |
Sep 2007 | - | $9.80 M(+6.8%) |
Jun 2007 | - | $9.18 M(+40.1%) |
Mar 2007 | - | $6.55 M(+2089.2%) |
Dec 2006 | $16.98 M(-11.2%) | $299.30 K(-94.6%) |
Sep 2006 | - | $5.54 M(-2.4%) |
Jun 2006 | - | $5.67 M(+8.0%) |
Mar 2006 | - | $5.25 M(-1.0%) |
Dec 2005 | $19.12 M(+18.1%) | $5.30 M(+13.1%) |
Sep 2005 | - | $4.69 M(+1.8%) |
Jun 2005 | - | $4.60 M(+12.0%) |
Mar 2005 | - | $4.11 M |
Dec 2004 | $16.19 M(+36.8%) | - |
Dec 2003 | $11.83 M | - |
FAQ
- What is Mirati Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Mirati Therapeutics?
- What is Mirati Therapeutics annual operating expenses year-on-year change?
- What is Mirati Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly operating expenses year-on-year change?
What is Mirati Therapeutics annual total operating expenses?
The current annual operating expenses of MRTX is $771.42 M
What is the all time high annual operating expenses for Mirati Therapeutics?
Mirati Therapeutics all-time high annual total operating expenses is $771.42 M
What is Mirati Therapeutics annual operating expenses year-on-year change?
Over the past year, MRTX annual total operating expenses has changed by +$126.15 M (+19.55%)
What is Mirati Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of MRTX is $186.77 M
What is the all time high quarterly operating expenses for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly total operating expenses is $212.06 M
What is Mirati Therapeutics quarterly operating expenses year-on-year change?
Over the past year, MRTX quarterly total operating expenses has changed by -$5.11 M (-2.66%)